Press Releases

Date Title and Summary
Toggle Summary Webcast Alert: Isis Pharmaceuticals' Second Quarter 2015 Financial Results Conference Call
Toggle Summary Isis Pharmaceuticals Reports Data From ISIS-TTR Rx in Patients With Transthyretin Amyloid-Related Cardiomyopathy
Toggle Summary Positive Clinical Data From Lp(a) Lowering Drug ISIS-APO(a) Rx Published in The Lancet
Toggle Summary Isis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx in Patients With Huntington's Disease
Toggle Summary Isis Pharmaceuticals Earns $2.15M for Advancing ISIS-SMN Rx in Children With Spinal Muscular Atrophy
Toggle Summary Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome
Toggle Summary Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting
Toggle Summary Isis Pharmaceuticals Promoted to the Large-Cap Russell 1000 Index
Toggle Summary Isis Pharmaceuticals Reports Data from ISIS-SMN Rx in Children with Spinal Muscular Atrophy
Toggle Summary Isis Pharmaceuticals to Present a General Corporate Update at its 2015 Annual Meeting of Stockholders and Open House
Toggle Summary Isis Pharmaceuticals Reports Data From ISIS-SMN Rx Phase 2 Study in Infants With Spinal Muscular Atrophy
Toggle Summary Isis Pharmaceuticals to Host Webcast to Discuss Data From ISIS-SMN Rx Phase 2 Study in Infants With Spinal Muscular Atrophy
Toggle Summary Isis Pharmaceuticals' License Agreement With Bayer for ISIS-FXI Rx Receives Hart-Scott-Rodino Approval
Toggle Summary Isis Pharmaceuticals to Present at the Goldman Sachs 36th Annual Global Healthcare Conference
Toggle Summary Webcast Alert: Akcea Therapeutics Conference Call
Toggle Summary Isis Reports Financial Results and Highlights for First Quarter 2015
Toggle Summary Isis Pharmaceuticals Licenses ISIS-FXI Rx to Bayer to Develop and Commercialize for the Prevention of Thrombosis
Toggle Summary Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen
Toggle Summary Webcast Alert: Isis Pharmaceuticals' First Quarter 2015 Financial Results Conference Call
Toggle Summary Isis Pharmaceuticals Reports Positive Data From ISIS-TTR Rx in Patients With TTR Amyloidosis
Toggle Summary Isis Pharmaceuticals to Present at Upcoming Investor Conferences
Toggle Summary Isis Pharmaceuticals Reports Positive Phase 1 Data on Isis-ANGPTL3Rx
Toggle Summary Isis Pharmaceuticals Earns $9M for Advancing ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
Toggle Summary Isis Pharmaceuticals Earns $15 Million From GSK for Advancing ISIS-TTR Rx
Toggle Summary Isis Reports Financial Results and Highlights for 2014
Toggle Summary ISIS Pharmaceuticals Reports Positive Phase 1 Data Demonstrating ISIS-PKK Rx Produces Significant Reductions in Prekallikrein Levels
Toggle Summary Webcast Alert: Isis Pharmaceuticals' 2014 Financial Results and Highlights Conference Call
Toggle Summary Isis Pharmaceuticals Earns $5 Million Milestone Payment From Biogen Idec
Toggle Summary Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancing New Drug Into Development to Treat a Neurodegenerative Disease
Toggle Summary Isis Pharmaceuticals to Present at Upcoming Investor Conferences
Toggle Summary Isis Pharmaceuticals Reports Data From Phase 2 Study of ISIS-PTP1B Rx in Patients With Type 2 Diabetes
Toggle Summary Isis Pharmaceuticals Earns $7M for Advancing ISIS-SMN Rx in Children With Spinal Muscular Atrophy
Toggle Summary Alnylam and Isis Form New Agreement, Extending Decade-Long Partnership for Leadership in RNA Therapeutics
Toggle Summary Isis Pharmaceuticals Significantly Improves Upon 2014 Financial Guidance
Toggle Summary Isis Pharmaceuticals Appoints Paula Soteropoulos As President And Chief Executive Officer Of Akcea Therapeutics
Toggle Summary Isis Pharmaceuticals Appoints Sarah Boyce As Chief Business Officer
Toggle Summary Isis Pharmaceuticals Announces Collaboration With Janssen to Discover and Develop RNA-Targeted Therapeutics for Autoimmune Diseases in the GI Tract
Toggle Summary Isis Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Toggle Summary Isis Pharmaceuticals Initiates Phase 1/2 Study of ISIS-DMPK Rx in Patients With Myotonic Dystrophy Type 1
Toggle Summary Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
Toggle Summary Isis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Prestigious SCRIP Lifetime Achievement Award
Toggle Summary ISIS-APOCIII Rx Phase 2 Study in Patients With Familial Chylomicronemia Published in the New England Journal of Medicine
Toggle Summary Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Children With Spinal Muscular Atrophy
Toggle Summary ISIS-STAT3 Rx and ISIS-AR Rx Data Presented by AstraZeneca at European Cancer Symposium
Toggle Summary Genzyme and Isis Present KYNAMRO® Clinical Data at the American Heart Association
Toggle Summary Isis Pharmaceuticals to Host Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting
Toggle Summary Cure SMA Presents Isis Pharmaceuticals with SMA Breakthrough Award
Toggle Summary Isis Pharmaceuticals to Present at Upcoming Investor Conferences
Toggle Summary AstraZeneca and Isis Pharmaceuticals to Co-Develop Targeted Oligonucleotide Delivery Methods
Toggle Summary Isis Pharmaceuticals Prices Offering of $425 Million of 1.00% Convertible Senior Notes
Toggle Summary Isis Pharmaceuticals Announces Proposed Offering of $425 Million of Convertible Senior Notes
Toggle Summary Isis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2014
Toggle Summary Isis Pharmaceuticals Earns $10 Million Milestone Payment From Biogen Idec for Advancement of ISIS-BIIB3 Rx
Toggle Summary Isis Pharmaceuticals Earns $7.5 Million Milestone Payment From AstraZeneca
Toggle Summary Isis Pharmaceuticals Earns $5 Million in Milestone Payment From GSK for Advancement of ISIS-GSK5 Rx
Toggle Summary Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call
Toggle Summary Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference
Toggle Summary Isis Pharmaceuticals Reports Data From ISIS-SMN Rx Phase 2 Studies in Infants and Children With Spinal Muscular Atrophy
Toggle Summary Isis Pharmaceuticals Earns $18 Million From GSK for Advancing ISIS-TTR Rx
Toggle Summary Isis Pharmaceuticals to Host Webcast to Discuss ISIS-SMN Rx Results Presented at the World Muscle Society Congress
Toggle Summary Isis Pharmaceuticals Earns $1.5 Million From GSK for the Advancement of ISIS-GSK4 Rx
Toggle Summary Isis Pharmaceuticals to Present at the Leerink Partners Rare Disease Roundtable
Toggle Summary Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin
Toggle Summary Isis Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference
Toggle Summary Drugs from Isis' Lipid Franchise Highlighted at European Society of Cardiology Congress 2014
Toggle Summary Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-APOCIII Rx in Patients with FCS
Toggle Summary Isis Pharmaceuticals Earns $2M from the Advancement of ISIS-SMN Rx in Children with Spinal Muscular Atrophy
Toggle Summary Isis Reports Financial Results and Highlights for Second Quarter 2014
Toggle Summary Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy
Toggle Summary Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call
Toggle Summary Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-APO(a) Rx in Patients with High Lp(a)
Toggle Summary Isis Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx
Toggle Summary Isis Pharmaceuticals Earns $1 Million From GSK for Advancing Hepatitis B Virus Program
Toggle Summary Isis Pharmaceuticals Earns $1 Million From GSK for Advancing ISIS-TTR Rx
Toggle Summary Isis Pharmaceuticals Earns $10 Million Milestone Payment from Biogen Idec
Toggle Summary Isis Pharmaceuticals Reports Final Phase 2 Data on ISIS-GCGR RX Showing Significant Reduction in HbA1c in Patients with Type 2 Diabetes
Toggle Summary Isis Pharmaceuticals to Present at the 2014 Wells Fargo Healthcare Conference
Toggle Summary Isis Pharmaceuticals to Host Investor Event to Discuss ISIS-GCGR Rx Phase 2 Data Presented at the 2014 ADA Scientific Sessions
Toggle Summary Isis Pharmaceuticals Earns $15 Million from AstraZeneca for Initiation of Phase 1 Study of ISIS-AR Rx
Toggle Summary Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-DMPK Rx to Treat Myotonic Dystrophy Type 1
Toggle Summary Isis Pharmaceuticals to Present at the Goldman Sachs 35th Annual Global Healthcare Conference
Toggle Summary Isis Pharmaceuticals to Present a General Corporate Update at its 2014 Annual Meeting of Stockholders and Open House
Toggle Summary Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
Toggle Summary Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-PKK Rx
Toggle Summary Webcast Alert: Isis Pharmaceuticals Announces its R&D Day Presentation
Toggle Summary Isis Pharmaceuticals Earns $3.0 Million from GSK
Toggle Summary Isis Pharmaceuticals Reports Phase 2 Data on ISIS-GCGR Rx Showing Significant Reduction in HbA1c in Patients With Type 2 Diabetes
Toggle Summary Isis Pharmaceuticals to Present at the UBS Global Healthcare Conference
Toggle Summary Genzyme and Isis Receive Corporate Award from the National Organization for Rare Disorders (NORD) for the Development of KYNAMRO®
Toggle Summary Isis Pharmaceuticals to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
Toggle Summary Isis Reports Financial Results and Highlights for First Quarter 2014
Toggle Summary Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx in Patients With Familial Chylomicronemia
Toggle Summary Isis Pharmaceuticals to Present at the Deutsche Bank 39th Annual Health Care Conference
Toggle Summary Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx in Patients With High Triglycerides and Type 2 Diabetes
Toggle Summary Webcast Alert: Isis Pharmaceuticals' First Quarter 2014 Financial Results Conference Call
Toggle Summary ISIS Pharmaceuticals' and Biogen idec's innovative collaboration voted breakthrough alliance of 2014
Toggle Summary Isis Reports Updated Results from ISIS-SMN Rx Clinical Studies in Infants and Children with Spinal Muscular Atrophy
Toggle Summary Isis Pharmaceuticals to Host Investor Event to Discuss ISIS-SMN Rx Data Presented at the 2014 AAN Annual Meeting
Toggle Summary Isis Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference
Toggle Summary Isis Reports Final Phase 2 Data On ISIS-APOCIII Rx In Patients With High Triglycerides Taking Fibrates
©1999 - 2017 Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc.